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Aim: To demonstrate quantitative assessment of tumor response to treatment in patients with follicular lymphoma using parallel 
monitoring of minimal residual disease (MRD) and diffusion-weighted MRI (MRI-DWI) derived apparent diffusion coefficient (ADC). 
Materials and Methods: Two patients with follicular lymphoma were undergone synchronous evaluation of MRD and MRI-DWI 
at definite time points before, during and after chemotherapy. MRD level was calculated in diagnostic and follow up samples relative 
to the highest level of amplification of the target. Allele-specific primer for clonal IgH gene rearrangement was used as a target for 
real-time quantitative polymerase chain reaction (PCR). 1.5 Tesla scanner was used for MRI-DWI. The largest non necrotic lymph 
node was chosen for serial ADC measurement. Results: In first patient MRD reduced drastically in blood after chemotherapy but 
persisted at low level in bone marrow. Whole body MRI-DWI demonstrated regression of most of tumor lesions except one  marginally 
enlarged iliac lymph node and allowed to predict tumor progression in this particular anatomical site based on low ADC value after 
treatment. In the second patient all three methods (MRD, ADC and radiologic evaluation) gave concordant result of complete tumor 
response and patient remained in a clinical remission during follow-up time. Conclusion: Quantitative PCR measurement may detect 
very low level of MRD in patients with follicular lymphoma which may have prognostic value. Combination of both PCR-based MRD 
and quantitative evaluation of MRI-DWI derived ADC provides safe added-value disease monitoring in lymphoma.
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Achievements in the field of non-Hodgkin lym-
phomas (NHL) molecular biology lead to progressive 
development of treatment personalization. At the same 
time they provide an option for accurate response 
monitoring and prognostication. A range of laboratory 
molecular techniques are available in lymphoma [1]. 
Evaluation of minimal residual disease (MRD) is used 
as supporting and additional data which help in re-
sponse assessment fulfilled by conventional clinical 
and diagnostic imaging methods [2]. MRD is defined 
as any approach aimed at detecting and possibly quan-
tifying residual tumor cells beyond the sensiti vity level 
of routine imaging and laboratory techniques [3]. MRD 
has established role in leukaemias where it is used 
to detect persistent leukaemic cells in bone marrow 
or blood. High sensitivity of the test allows detecting 
leukaemic cells at level down to one cell per million. 
It was shown that MRD level after chemotherapy for 
acute lymphoblastic leukaemia is closely related to the 
probability of relapse [4]. To lesser extent MRD was 
studded in patients with indolent NHL, primarily fol-
licular and mantle cell lymphomas [5–7].
Computed tomography (CT) or 18F-fluorodeoxy-
glucose-PET are standard methods for diagnostics, 
response evaluation and follow-up of patients with 
NHL. Before, during and after treatment numerous 
CT and FDG-PET exams are performed that leads 
to accumulation of ionizing radiation dose and increasing 
risk of secondary malignancy development, especially 
in children and young patients [8, 9]. MRI with diffu-
sion-weighed imaging (MRI-DWI) is a radiation-free 
and highly sensitive method for detection of nodal 
and extranodal lesions in lymphoma [10, 11]. DWI 
is a MRI pulse sequence specially designed to detect 
microscopic water molecules movement in tissues 
and fluids in vivo. In solid tumors water diffusion takes 
place mainly in the intercellular spaces. In lymphomas 
diffusion in restricted because of increased cellular 
density and high nuclear to cytoplasm ratio allowing 
to characterize tumor at the cellular level. Because 
of high safety profile MRI-DWI may be repeated during 
and after treatment as many times as needed for treat-
ment monitoring and follow-up. Another advantage 
of DWI compared to other MRI pulse sequences 
is a quantitative evaluation using apparent diffusion 
coefficient (ADC). Solid malignant tumors including 
lymphomas are characterized by low ADC, generally 
below 1–1.2•10–3 mm2/s [12, 13]. During effective cy-
totoxic treatment ADC increases because of cell death 
mechanisms such as apoptosis and necrosis [14]. 
Due to quantitative nature MRD and MRI-DWI might 
be used in parallel to monitor tumor response in NHL.
MATERIALS AND METHODS
In frame of clinical projects “Idiotype DNA vaccines 
for B-cell NHL” and “MRI-DWI diagnostics in patients 
with lymphomas” synchronous evaluation of MRD and 
MRI-DWI derived ADC was performed in 2 patients with 
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follicular lymphoma at the definite time points before, 
during and after treatment. Patients got standard 
diagnostic imaging tests for tumor staging, response 
evaluation and follow-up according to current practice 
in our institution.
MRD detection was performed as previously de-
scribed [15]. DNA from primary removed neck lymph 
node was used for target identification and standard 
curve construction. Allele-specific primer for clonal 
IgH gene rearrangement was used as a target for real-
time quantitative polymerase chain reaction (RQ-PCR) 
measurement [16]. MRD level was calculated in diag-
nostic and follow up samples relative to the highest 
level of amplification of the target.
1.5 Tesla scanner was used for MRI-DWI. Scanning 
technique was previously described [11]. Staging and 
treatment response assessment was based on whole 
body MRI-DWI. For serial ADC measurement the 
largest non necrotic lymph node (target lesion) was 
chosen on staging MRI-DWI. Lymph node was con-
toured on three diffusion-weighted images with largest 
tumor dimensions using scanner software. Contours 
were automatically transferred to corresponding ADC 
maps. Mean signal intensity on ADC map corresponds 
to tumor ADC value. ADC values on three slices were 
averaged in order to get a lesion ADC.
RESULTS AND DISCUSSION
A 28-year-old woman (patient 1) was diagnosed 
with follicular B-cell NHL involving axillary, me-
diastinal, mesenteric, paraaortic, iliac lymph nodes 
and bone marrow, Ann Arbor stage IV (Figure). Im-
munohistochemistry: CD20+++, CD5−, CD3−, cyclin 
D1−, CD21−, CD23−, Ki-67 up to 20%. A patient was 
undergone to eight courses of chemotherapy FC 
(fludarabine, cyclophosphamide). Before and after 
first, before and after second, before third course and 
after chemotherapy (8 courses) synchronous quan-
titative evaluation of MRD and ADC was performed 
(Table 1). During chemotherapy PCR-based MRD 
reduced drastically in blood but persisted at low level 
in bone marrow. Paraaortic lymph node measuring 
6.2×4.2 cm was chosen for serial ADC evaluation. 
ADC value of target lesion increased gradually from 
0.51 to 1.59•10–3 mm2/s corresponding to size nor-
malization of most lymph nodes at restaging except 
right iliac one. ADC value of this lymph node was still 
low at the end of treatment (0.95•10–3 mm2/s) showing 
chemotherapy resistance. Tumor progression deve-
loped in this region one month later.
a b
Figure. Whole body DWI of patient 1 with follicular lymphoma 
before treatment (a) and after 8 courses of chemotherapy (b). 
Inverted gray scale maximum intensity projection images are 
presented. Axillary, mediastinal, mesenteric, paraaortic and iliac 
lymph nodes were initially involved (a). After chemotherapy all 
lesions regressed except right iliac lymph node (arrow on b). 
Physiologic diffusion restriction in the brain, spinal cord, spleen, 
ovaries and endometrium is noted
Table 1. Serial MRD, ADC and radiological evaluation in patient 1 with follicular NHL
Time point MRD ADC, ×10–3 mm2/s Radiologic evaluation
1 month before treatment Tissue of lymph node 85.85%Peripheral blood 2.52% − −
Staging immediately before treatment Peripheral blood 15%Bone marrow 100%
Paraaortic lymph node 0.51
Right iliac lymph node 0.59
Whole body MRI-DWI: lesions of left axillary, mediastinal, 
mesenteric, paraaortic, iliac lymph nodes and bone marrow
Immediately after FC 1 − Paraaortic lymph node 0.75 −
Immediately before FC 2 Peripheral blood 0.002% Paraaortic lymph node 0.96 −
Immediately after FC 2 Peripheral blood 0.008% Paraaortic lymph node 1.15 −
Immediately before FC 3 Peripheral blood 0% Paraaortic lymph node 1.19 −
Restaging after 8 courses of che-
motherapy (partial response)
Peripheral blood 0%
Bone marrow 0.002%
Paraaortic lymph node 1.59
Right iliac lymph node 0.95
Whole body MRI-DWI: upper diaphragm all  lesions 
 regressed, lower diaphragm — right iliac lymph 
nodes up to 1.3 cm
Follow-up 2 months after treatment 
(progression) Peripheral blood 0.002% − Ultrasound: right iliac lymph node enlarged to 2.5×1.6 cm
4 months follow-up (further pro-
gression) Peripheral blood 0.009% −
CT scan: right iliac lymph node enlarged to 4.9×4.5 cm, 
all other lymph nodes are normal in size
Table 2. Serial MRD, ADC and radiological evaluation in patient 2 with follicular NHL
Time point MRD ADC, ×10–3 mm2/s Radiologic evaluation
Staging before treatment Tissue of lymph node 100% 
Peripheral blood 75,67%
Left iliac lymph node 0.54 Whole body MRI-DWI: lesions of cervical, supracla-
vicular, infraclavicular, axillary, mediastinal, mesen-
teric, paraaortic, iliac, inguinal lymph nodes, spleen 
and bone marrow
Restaging after 8 courses of chemotherapy 
(complete response)
Peripheral blood 0% Left iliac lymph node 1.53 Whole body MRI-DWI: all lesions regressed
Follow-up 5 months after treatment (remission) Peripheral blood 0% − Abdominal and pelvic MRI-DWI: no lesions detected
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A patient 2 is a 43-year-old woman diagnosed with 
follicular B-cell NHL involving cervical, supraclavicular, 
infraclavicular, axillary, mediastinal, mesenteric, para-
aortic, iliac, inguinal lymph nodes, spleen and bone 
marrow, Ann Arbor stage IV. Immunohistochemistry: 
CD20+++, bcl6+++, CD10+++, bcl2++, CD21−/+, cyclin D1−, 
CD5−, CD3−, Ki-67 more than 40%. A patient was un-
dergone to eight courses of chemotherapy R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincris-
tine, prednisolon). Before and after chemotherapy 
(8 courses) synchronous quantitative evaluation of MRD 
and ADC was performed (Table 2). Left iliac lymph node 
was chosen as a target for ADC measurement. After end 
of chemotherapy MRD was not detectable in the blood 
any more, target lesion ADC increased to the level above 
1.5•10–3 mm2/s and radiological evaluation showed 
complete response of all tumors. Patient remains in re-
mission during 6 months of follow-up.
In this report we present clinical cases of two pa-
tients with follicular NHL treated with chemotherapy 
with serial MRD and MRI-DWI examination. Results 
of MRD, ADC and radiological evaluation at different 
time points before, during and after treatment are 
presented. In patient 1 whole body MRI-DWI after 
eight courses of chemotherapy demonstrated regres-
sion of most of tumor lesions. Only iliac lymph node 
remained marginally enlarged measuring 1.3 cm. Such 
small lymph nodes might be difficult to detect and even 
more difficult to characterize by conventional imaging 
techniques such as CT, ultrasonography or MRI. DWI 
with ADC calculation is a functional imaging technique 
which allowed to predict tumor progression in this par-
ticular anatomical site based on low ADC value after 
treatment. In the patient 2 all three methods (MRD, 
ADC and radiologic evaluation) gave concordant result 
of complete tumor response and patient remained 
in a clinical remission during follow-up time.
In the published literature MRD was used in patients 
with indolent lymphomas for molecular monitoring 
of treatment response and as a surrogate marker for 
prognosis. In follicular lymphoma negative PCR-based 
MRD status after rituximab treatment predicted higher 
freedom from recurrence rate — 57% compared with 
20% in patients with molecular positivity [6]. In ad-
vance stage follicular lymphoma patients achieved 
an adequate remission with induction therapy PCR 
detectable disease in the bone marrow before au-
tologous stem cell transplantation was the strongest 
predictor of decreased progression-free survival [17]. 
To best of our knowledge our report is the first one 
correlating MRD with relatively new quantitative func-
tional imaging technique — diffusion-weighted MRI 
with ADC calculation.
In conclusion, quantitative PCR measurement may 
detect very low level of MRD in patients with follicular 
lymphoma which may have prognostic value. Combi-
nation of both PCR-based MRD and quantitative evalu-
ation of MRI-DWI derived ADC provides added-value 
disease monitoring in lymphoma.
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